Ascendis Pharma A/S (ASND)

NMS – Real Time Price. Currency in USD

254.41

-0.16 (-0.06%)

Market open: Aug 12, 2026, 2:04 PM EDT

254.57

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

06.08.2026

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on August 13, 2026, at 8:00 a.m.

06.08.2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided updates across its achondroplasia programs.

Videos

No Data

There is no data to display

Press releases

06.08.2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided updates across its achondroplasia programs.

Ascendis Pharma A/S (ASND)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ascendis Pharma A/S (ASND)

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Videos

No Data

Press releases

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Videos

No Data

Press releases

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Search stocks

Ascendis Pharma A/S (ASND)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ascendis Pharma A/S (ASND)

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Videos

No Data

Press releases

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Videos

No Data

Press releases

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.